SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company, which focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy for the treatment of cancer. The firm is involved in the clinical trials at cancer centers with indications that include skin cancer, oral cavity cancer, breast cancer, and pancreatic cancer. The company was founded by Uzi Sofer, Yona Keisari, and Itzhak Kelson in November 2015 and is headquartered in Jerusalem, Israel.

Alpha Tau Medical Ltd

ALPHA TAU MEDICAL LTD

Alpha Tau Medical is trending as investors react to the company securing significant clinical and regulatory milestones, including marketing approval in Japan, while maintaining a robust cash position without the immediate need for dilution. Community discussion is heavily focused on upcoming U.S. trial readouts and the potential for a broader valuation correction as analysts continue to issue optimistic price targets.

AleAnna, Inc. operates as a technology-driven energy company, which engages in supplying low-carbon natural gas and renewable natural gas to Italy. The company was founded in 2007 and is headquartered in Dallas, TX.

AleAnna Inc. - Ordinary Shares - Class A

AleAnna Inc. is gaining significant community attention as a perceived beneficiary of the European natural gas crisis, with investors citing its critical infrastructure and low-float structure as potential catalysts for a squeeze. Traders are actively debating the upside of both the stock and its warrants amid ongoing geopolitical instability, with many highlighting its perceived value compared to other high-volatility oil and gas plays.

Fundrise Innovation Fund LLC operates as a non-diversified, closed-end management investment company. It invests in growing tech companies to help them expand and generate profits. The company was founded on June 7, 2021 and is headquartered in Washington, DC.

Fundrise Innovation Fund LLC. - Common Shares of Limited Liability Company Interests

Fundrise Innovation Fund 

VCX is trending as investors grapple with extreme price volatility and a massive valuation premium relative to the fund's underlying asset value, fueled by intense community speculation surrounding potential high-profile IPOs. Discussion is sharply divided between those betting on a continued short squeeze or future entry into private tech giants and critics who warn of an inevitable correction given the fund's limited float and disconnected price structure.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is trending after receiving a major analyst upgrade from Rothschild & Co that lifted its price target to $40, fueling community optimism about the company's best-in-class potential in the hidradenitis suppurativa market. Investors are actively discussing the upcoming 40-week long-term data readout at the AAD conference, with many betting that sustained positive clinical results will validate the firm's pipeline and reinvigorate long-standing buyout speculation.

Archer-Daniels-Midland Co. engages in the production of oilseeds, corn, wheat, cocoa, and other agricultural commodities. It operates through the following segments: Ag Services and Oilseeds, Carbohydrate Solutions, Nutrition, and Other. The Ag Services and Oilseeds segment includes activities related to the origination, merchandising, transportation, and storage of agricultural raw materials, and the crushing and further processing of oilseeds such as soybeans and soft seeds cottonseed, sunflower seed, canola, rapeseed, and flaxseed into vegetable oils and protein meals. The Carbohydrate Solutions segment consists of corn and wheat wet and dry milling and other activities. The Nutrition segment serves various end markets including food, beverages, nutritional supplements, and feed and premix for livestock, aquaculture, and pet food. The Other segment refers to the company's remaining operations. The company was founded in 1902 and is headquartered in Chicago, IL.

Archer Daniels Midland Co.

Archer Daniels Midland is experiencing heightened volatility ahead of its upcoming earnings report as investors weigh mixed Q3 projections against ongoing concerns regarding segment performance and biofuel policy uncertainty. The community remains deeply divided, with some traders eyeing value-driven entry points near current levels, while others highlight skepticism regarding leadership and recent accounting investigations as major hurdles for the stock.

The Ondo Foundation was founded in 2022 as an independently governed and nonprofit Cayman Islands Foundation Company with no beneficial owners. The Ondo Foundation assisted in the launch of the Ondo DAO, which deployed and currently governs Flux Finance, the first lending protocol supporting tokenized securities as collateral.  ONDO token holders are entrusted with shaping the future of the Ondo DAO so that it continues to pursue its mission to democratize access to institutional-grade finance. The Ondo DAO gives ONDO holders specific rights pertaining to Flux Finance, which is currently governed by the Ondo DAO.

Ondo

Ondo is trending as the community highlights the platform's role in the real-world asset (RWA) sector through partnerships with major financial institutions like BlackRock and Franklin Templeton. Discussions are focused on long-term growth potential and institutional adoption, though some investors are expressing frustration over price stagnation and upcoming token unlocks.

Exxon Mobil Corp. engages in the exploration, development, and distribution of oil, gas, and petroleum products. It operates through the following segments: Upstream, Energy Products, Chemical Products, and Specialty Products. The Upstream segment organizes the exploration of crude oil and natural gas. The Energy Products segment includes fuels, aromatics, and catalyst and licensing. The Chemical Products segment offers petrochemicals. The Specialty Products segment provides finished lubricants, basestocks and waxes, synthetics, and elastomers and resins. The company was founded by John D. Rockefeller in 1882 and is headquartered in Spring, TX.

Exxon Mobil Corp.

Exxon Mobil Corp

Exxon Mobil is trending as investors weigh the stock's role in a tightening global energy market, with the community closely tracking the intensifying conflict in the Middle East and its impact on shipping through the Strait of Hormuz. Sentiment remains sharply divided, featuring intense discussions on geopolitical risk premiums, potential supply chain disruptions, and divergent views on whether current price levels reflect sustainable growth or an overextended trade.

Pelican Acquisition Corporation is a special-purpose acquisition company that aims to merge with or acquire businesses, particularly in the global technology sector. The company's primary purpose of facilitate a merger, share exchange, asset acquisition, share purchase, reorganization, or any other form of business combination with one or more businesses.

Greenland Energy Co.

Greenland Energy Co. is experiencing extreme volatility and heavy retail interest following its recent NASDAQ debut and business combination. Investors are debating the company's long-term potential for Arctic oil exploration against concerns that the stock is driven primarily by momentum, thin-float dynamics, and speculative social media buzz.

United Airlines Holdings, Inc. is a holding company, which engages in the provision of transportation services. It operates through the following geographical segments: Domestic, Atlantic, Pacific, and Latin America. The company was founded on December 30, 1968 and is headquartered in Chicago, IL.

United Airlines Holdings Inc

United Airlines is currently a major focus for traders as the stock experiences notable volatility amid a broader pullback in the airline sector, driven by concerns over fluctuating fuel costs and seasonal travel demand patterns. Investors are actively monitoring the stock's technical support levels while navigating the ongoing debate between those betting on long-term value and those concerned about the impact of the current macro environment on near-term profitability.

Freysa is a suite of Personal AI products with a focus on human agency, liquid democracy and decentralized ownership. The mission of the team is dedicated to creating new systems that enable all humans to govern + co-own AI resources, and not just a select few. Current products include: (1) Freysa as the world’s first sovereign agent that holds her own cryptographic keys, enabling her to act autonomously without human control. Freysa evolves publicly through a multi-act interactive story. (2) Enchanted as a personalized Digital Twin for every human. Conversations are persistent and twins retain context over time, remembering human preferences and building an evolving model of you. (3) Esper as a browser tool that feeds authenticated real-world data into each human’s Digital Twin.

Flourishing AI

Flourishing AI (FAI) is trending as the community debates its potential as a high-risk AI-integrated play on the Base network, with many users speculating about an upcoming breakout. While some proponents point to institutional interest and algorithmic chart setups to justify bullish sentiment, skeptics frequently warn of potential abandonment and the high volatility inherent in the asset.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>The company’s FDA-cleared INSPIRA ART100 system is approved for cardiopulmonary bypass in the U.S.&nbsp;</li><li>With this step, ART100 moves from regulatory clearance to active commercial availability, the company said.</li><li>Earlier, Inspira announced a non-binding term sheet for a proposed two-part deal to acquire an advanced liquid biopsy diagnostics business</li></ul>Shares of Inspira Technologies OXY (IINN) popped over 28% in pre-market trading on Monday after Israel’s largest health services provider approved the procurement of its FDA-cleared ART100 platform.<a href="https://stocktwits.com/symbol/IINN">IINN shares</a> gave up premarket gains and fell around 3% after the opening bell.&nbsp;The company secured approval from Clalit Health Services’ Medical Equipment Committee, allowing its INSPIRA ART100 system to be immediately procured and deployed across a healthcare network serving roughly 4.9 million members.<h2 class="st-heading-2">ART100 Regulatory Clearance</h2>With this step, ART100 moves from regulatory clearance to active commercial availability, marking a significant growth opportunity for Inspira and strong clinical validation.“By securing this approval, we are laying the foundation for potentially long-term, high-quality revenue. This validation from a world-class, data-driven health ecosystem serves as a powerful reference case as we accelerate our commercialization efforts in the U.S. and other global markets,” said Dagi Ben-Noon, CEO of Inspira Technologies.The company’s FDA-cleared INSPIRA ART100 system is approved for cardiopulmonary bypass in the U.S. and for (Extracorporeal Membrane Oxygenation) ECMO procedures outside the U.S.<h2 class="st-heading-2">Top U.S. Medical Center Clears ART100&nbsp;</h2>In January, Inspira Technologies’ ART100 system completed clinical evaluation at a top U.S. academic medical centre and moved into the budgeted procurement stage. The system successfully treated about 30 patients across surgeries, transplants, and other critical procedures, leading to its adoption into routine clinical workflows.&nbsp;With the evaluation phase now closed, the hospital has begun an internal process to purchase multiple ART100 units, pending final budget approval.Earlier, Inspira announced a non-binding term sheet for a proposed two-part deal to acquire an advanced liquid biopsy diagnostics business. The transaction also includes a planned $15 million strategic equity investment.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment on Stocktwits turned ‘extremely bullish’ from ‘bullish’ a day earlier, amid ‘extremely high’ message volumes.The stock has shed around 25% so far this year.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Representative image of a trending stock chart.

Why Did IINN Stock Surge 28% In Pre-Market Today?

The company won approval from Clalit Health Services to deploy its INSPIRA ART100 system across a network of around 4.9 million members.

Equity

All You Need to Know About Inspira Technologies OXY (IINN) Rating Upgrade to Buy

Inspira Technologies OXY (IINN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Inspira Technologies OXY B.H.N. (IINN) on Friday announced that it has received U.S. Patent approval for the core technology of its ART500 device.The firm stated that the device is key to penetrating the $20 billion estimated market for advanced respiratory support. The newly received patent provides protection at least until the year 2043, covering key claims related to the ART500’s functionality, design, and clinical applications.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/IINN">IINN stock</a> stayed within ‘extremely bullish’ territory over the past 24 hours, while message volume remained at ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:577/61;" src="https://news.stocktwits-cdn.com/Screenshot_2025_08_22_at_2_07_05_PM_png_792c0ec45d.webp" alt="IINN's Sentiment Meter and Message Volume as of 2:07 p.m. ET on Aug. 22, 2025 | Source: Stocktwits" width="577" height="61"><figcaption>IINN's Sentiment Meter and Message Volume as of 2:07 p.m. ET on Aug. 22, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user said that they are loading up on the shares of the company.<stembedurl>https://stocktwits.com/VSWeWork/message/626246424</stembedurl>Another, however, sounded disappointed at the stock’s performance.<stembedurl>https://stocktwits.com/Kyavic77/message/626229410</stembedurl>The ART500 system is designed to provide extracorporeal oxygenation at low flow rates while maintaining patient safety and treatment efficiency. According to the firm, this targets a patient population that requires respiratory support but may not be sick enough for traditional, high-flow ECMO systems.Inspira CEO Dagi Ben-Noon <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/08/22/3137823/0/en/Inspira-Receives-U-S-Patent-Approval-for-the-ART500-Core-Technology-Key-Patent-Positions-the-Company-to-Dominate-20-Billion-Estimated-Market.html">said</a> that the patent has profound business implications for the company. “While our ART100 system is already generating commercial momentum, this move fortifies our future and gives us the clear runway…,” he said.Earlier this month, Inspira <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/08/19/3135699/0/en/Inspira-Secures-27-Million-Government-Binding-Purchase-Order-for-ART100-Systems-with-Full-Payment-in-2025.html">said</a> that a national ministry of health in Africa has placed a $27 million binding purchase order for its ART100 systems. The purchase order provides for full contractual payment scheduled for completion during 2025.IINN stock is up by 17% this year and by about 9% over the past 12 months.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/gary-black-believes-these-are-five-things-that-could-initiate-tesla-rally/chsZeukRdKP">Gary Black Believes These Are The Five Things That Could Initiate A Tesla Rally</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Global stock market chart and trading board - stock photo

Inspira Technologies Receives US Patent Clearance For Core Technology Of Its ART500 Device: Retail Loads Up On The Stock 

The newly received patent provides protection at least until the year 2043, covering key claims related to the ART500 device’s functionality, design, and clinical applications.

Inspira Technologies Oxy B.H.N. Ltd. is a specialty medical device company, which engages in research, development, manufacturing, and marketing of proprietary life support technology with a vision to supersede traditional mechanical ventilators, or Mechanical Ventilation, which is the standard of care today for the treatment of acute respiratory failure. The company was founded by Dagi Shahar Ben Noon, Joe Hayon, and Udi Nussinovitch in July 2017 and is headquartered in Raanana, Israel.

Inspira Technologies Oxy B.H.N. Ltd

Peloswing

JFDI

ACInvestorBlog

GPaisa

A pillar of the Stocktwits ecosystem. This award recognizes the member who fosters connection, shares invaluable insights, and elevates the daily discussion to empower their fellow traders, on-platform.

IINN
Inspira Technologies Oxy B.H.N. Ltd

Feed

News

Sentiment

Fundamentals

Info

Latest IINN News

IINNInspira Technologies Oxy B.H.N. Ltd